Operating Segments (Tables)

12 Months Ended

Dec. 31, 2015

Operating Segments [Abstract]

Summary of segmental information

	For the Years Ended December 31,
	2015			2014
Revenues
Vaccines/BioDefense	$	8,754,418		$	6,756,388
BioTherapeutics		13,972			286,628
Total	$	8,768,390		$	7,043,016
Income (Loss) from Operations
Vaccines/BioDefense	$	1,263,709		$	807,164
BioTherapeutics		(4,487,988	)		(7,674,381	)
Corporate		(3,885,997	)		(3,894,132	)
Total	$	(7,110,276	)	$	(10,761,349	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	39,925		$	39,625
BioTherapeutics		199,661			199,196
Corporate		7,872			6,966
Total	$	247,458		$	245,787
Other Income (Expense), Net
Corporate	$	(1,209,887	)	$	3,437,505
Share-Based Compensation
Vaccines/BioDefense	$	111,960		$	114,920
BioTherapeutics		148,244			193,926
Corporate		394,277			411,304
Total	$	654,481		$	720,150

	As of December 31,
	2015		2014
Identifiable Assets
Vaccines/BioDefense	$	2,123,676	$	1,025,220
BioTherapeutics		76,183		204,308
Corporate		5,187,263		5,724,720
Total	$	7,387,122	$	6,954,248